Fast to infuse.

bIndividual doses are compared and based on an 88-kg (194-lb) person receiving a single dose for a joint bleed (NovoSeven® RT: 90 mcg/kg; FEIBA: 70 U/kg).cPatients are cautioned that the maximum injection or infusion rate must not exceed 2 units per kilogram of body weight per minute.

Fast bleed control.

Helps control joint bleeds in as few as 5 hours with a median of 2 doses.d

dBased on individual dosage for joint bleeds in people with hemophilia A or B with and without inhibitors.

Recombinant safety and a low rate of blood clots.

NovoSeven® RT is made without any human blood or plasma. It is the only FDA-approved recombinant bypassing agent for hemophilia with inhibitors. Recombinant manufacturing minimizes the possibility of viral contamination. And, clinical trials showed adverse events (blood clots) occurred in 0.2% of bleeding episodes.e

eIn people with congenital hemophilia.

What if I need surgery or a procedure?

We understand that you have concerns about controlling bleeds if you ever need surgery or a procedure. The good news is that NovoSeven® RT is approved by the FDA for treating people with hemophilia A or B with inhibitors during and after surgery and procedures.

In fact, in a clinical trial, NovoSeven® RT was proven to effectively control bleeds throughout the surgical process. Here are the results:

Talk with your doctor for more information on controlling bleeds during and after surgery or procedures.

What about surgery and procedures?

Approved for surgical use and procedures for patients with hemophilia A or B with inhibitors.

Hear from people who

share your experience.

New to treatment? It’s

easy to get started.

Recombinant manufacturing

minimizes risk of viral contamination

Selected Important Safety Information

WARNING: BLOOD CLOTS

Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Indications and Usage

NovoSeven® RT (Coagulation Factor VIIa [Recombinant]) is used for:

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and people with Glanzmann’s thrombasthenia who have a decreased or absent response to platelet transfusions

Treatment of bleeding and prevention of bleeding for surgeries and procedures in adults with acquired hemophilia

Important Safety Information

WARNING: BLOOD CLOTS

Serious blood clots that form in veins and arteries with the use of NovoSeven® RT have been reported.

Your healthcare provider should discuss the risks and explain the signs and symptoms of blood clots to you. Some signs of a blood clot may include pain, swelling, warmth, redness, or a lump in your legs or arms, chest pain, shortness of breath, or sudden severe headache and/or loss of consciousness or function.

Your healthcare provider should monitor you for blood clots during treatment with NovoSeven® RT.

Warnings and Precautions

NovoSeven® RT should be used with caution if you have an increased risk for blood clots, such as with disseminated intravascular coagulation (DIC), clogged arteries, crush injury, septicemia (an infection in the blood), uncontrolled bleeding after giving birth, history of heart disease, liver disease, limited movement following surgery, in elderly people, in newborns, or if you are taking aPCCs/PCCs (activated or nonactivated prothrombin complex concentrates) with NovoSeven® RT.

Allergic reactions, including serious whole body allergic reactions, have been reported with NovoSeven® RT. Tell your healthcare provider if you are allergic to NovoSeven® RT, any of its ingredients, or mice, hamsters, or cows. If you think you are having an allergic reaction, call your healthcare provider right away. Some signs of allergic reaction may include shortness of breath, rash, itching, redness of the skin, and fainting/dizziness.

People with Factor VII deficiency should be monitored by their healthcare provider for antibodies, which can cause NovoSeven® RT to stop working properly.

Side Effects

The most common and serious side effects are blood clots.

Tell your healthcare provider about any side effects that bother you or do not go away.

Use with Other Drugs

Blood clots may occur if NovoSeven® RT is given with Coagulation Factor XIII (13).